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A specific LC-MS/MS method was developed and validated for automated determination of codeine in human plasma, using on-
line solid phase extraction (SPE) system coupled with positive ion electrospray ionization tandem mass spectrometry. The method 
allowed plasma direct injection onto cartridge without sample pre-treatment. Total analysis time per run was 3 min, allowing high-
throughput for codeine determination. SPE on-line along a monolithic column (Chromolith Performance RP-18e, 100 mm x 4.6 mm) 
demonstrated to be highly effective in terms of backpressure, separation speed and peak asymmetry. Calibration curves range was 
linear 5.0-200 ng mL-1. Method showed an excellent intra-day and inter-day precision ranged from 2.34 to 7.25% (CV%) as well as 
great intra-day and inter-day accuracy, ranging from 97.64 to 110% (RE%). SPE-LC-MS/MS method provided selectivity, accuracy, 
precision, fastness and high-throughput to assess codeine pharmacokinetics in human plasma samples.
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INTRODUCTION
Codeine ,  7 ,8-d idehydro-4 ,5-epoxy-3-methoxy-17-
methylmorphinan-6-ol (methylmorphine) is a phenanthrene-derivative 
opiate agonist used in mild to moderate pain relief (Figure 1). Several 
studies have demonstrated that it is still a drug of choice for treating 
acute and chronic pain.1-5Although, many bioanalytical methods 
have been developed for determination of codeine by LC-MS/MS 
and CG-MS, such as toxicological and forensic aplicattions,6-13 
most of these methods are based on off-line liquid-liquid or solid 
phase extraction (SPE). These procedures require complex steps 
and laborious repetitive work for sample clean-up, which may not 
meet the requirement for high-throughput, robustness and speed in 
bioanalysis and pharmacokinetic studies.14 Hence, more reliable, 
accurate and fast analytical methods are required.
On-line SPE has been used as an alternative to traditional 
extraction, offering significantly higher assay efficiency due to 
chromatographic run time synchronized to sample extraction, 
resulting in notably decrease analysis time.15 Accordingly, monolithic 
silica columns improve conventional chromatographic techniques (C8 
and C18), allowing high-flow on-line extraction and higher throughput 
on sample analysis.16
This paper describes an improved, rapid, selective and sensitive 
on-line SPE-LC-MS/MS method for the determination of codeine 
in human plasma using tramadol as an internal standard (IS) and its 
application to a bioequivalence study.
EXPERIMENTAL
Chemicals
Codeine phosphate was obtained from U.S. Pharmacopeia 
(Rockville, MD) and tramadol (IS) was obtained from Biosintetica 
Farmaceutica LTDA. (Sao Paulo, Brazil). HPLC grade acetonitrile, 
methanol and acetic acid was purchased from J.T. Baker (Phillipsburg, 
NJ, USA). Water was purified using a Milli-Q Gradient System from 
Millipore (Sao Paulo, Brazil).
Instrumentation
On-line SPE was performed with a Prospekt-2 automated 
SPE system (Spark Holland, Emmen, Netherlands) including an 
autosampler (Endurance), a high pressure dispenser (HPD) and 
an automated cartridge exchanger module (ACE). SPE cartridges 
used were HySphere C18, HD, 7 mm (Spark Holland, Emmen, 
Netherlands). HPLC system used was Shimadzu LC-10ADVP 
pump (Kyoto, Japan). LC separation was run through a Chromolith 
Performance RP-18e (100 mm x 4.6 mm) column (Merck, Germany) 
with a SecurityGuard C-18 guard column (4 mm x 3 mm) from 
Phenomenex (Torrance, CA, USA). Mass spectrometry was performed 
in a Quattro LC triple-quadrupole (Waters, Milford, MA, USA) 
equipped with an API electrospray source operating in positive mode.
Standards and quality control samples preparation
Drug stock solutions were prepared separately at a concentration 
of 10 µg mL-1 in acetonitrile/water (1:1 v/v). Working solution of 
tramadol (IS) was prepared in the same solvent at concentration of 
70 ng mL-1. Codeine stock solution aliquots were used to spike blank 
human plasma in order to obtain calibration standards of 5.0, 10, 20, 
50, 100, 200 ng mL-1. Aliquots of 200 ng mL-1 samples were used to 
spike blank human plasma in order to obtain three levels of quality 
Figure 1. Molecular structure of codeine (A) and IS (B)
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control (QCs) at 15, 80, and 160 ng mL-1 (low, medium and high). 
Aliquots of 450 µL from calibration standards and quality controls 
were spiked with 50 µL IS work solution. Following these samples 
were rapidly mixed and centrifuged at 14000 rpm for 3 min and 
aliquots of 300 µL were transferred to 96-well plates.
Liquid chromatography, SPE and mass spectrometry 
conditions
The mobile phase was a mixture of acetonitrile/acetic acid 10 
mmol L-1 pH 3.5 (50:50, v/v) at a flow rate of 1 mL min-1. Analytical 
column was operated at room temperature (25 °C) and total run time 
was set for 3.0 min. Autosampler temperature was maintained at 4.0 
°C and was set to make 100 µL sample injection. The SPE sequence 
was: cartridges were solvated with 1 mL methanol (at 5.0 mL min-1) 
and equilibrated with 1 mL water (at 5.0 mL min-1) to obtain suitable 
conditions for analyte adsorption. Subsequently, 100 µL of spiked 
plasma was loaded onto cartridge using 0.5 mL of 10 mmol L-1 acetic 
acid. Then, the cartridge was washed with 4.0 mL of 10 mmol L-1 
acetic acid. After completion of SPE, cartridge was switched in-line 
with the LC-MS/MS mobile phase to elute the analyte onto the 
analytical column. 
The column effluent was split to 200 µL min-1 before it entered the 
mass spectrometer ESI source. Two channels of positive ion multiple 
reaction monitoring (MRM) modes were used to detect codeine and 
IS. The most abundant product ions were: m/z 215.2 from the parent 
ion m/z 300.0 for codeine and m/z 58.4 from the parent ion m/z 264.3 
for IS, respectively. Source temperature was optimized at 120 °C, 
desolvation temperature was 300 °C, and desolvation gas flow was 
550 L h-1. The capillary voltage was set at 3.0 kV, while cone energy 
for codeine and IS were 40 and 20 V, respectively. Collision energy 
was optimized for codeine (25 V) and IS (15 V). The multiplier was 
set at 750 V and cone gas flow was 110 L h-1. 
Validation study
The method was validated for selectivity, linearity, precision, 
accuracy, extract recovery and stability based upon ANVISA 
bioanalytical method guideline.17 Selectivity was determined 
analyzing six different blank human plasma (including six distinct 
lots of normal, lipemic and hemolyzed) spiked with codeine and IS 
(70 ng mL-1). To evaluate linearity, calibration curves with six codeine 
concentration levels (5.0-200 ng mL-1) were prepared and analyzed 
in duplicates three consecutive days. Standard curves were obtained 
by weighted least-squares regression (weighting = 1/x) of measured 
peak area ratios analyte/IS versus analyte concentrations added to 
plasma. Precision and accuracy were evaluated by analyzing six 
replicates at 15, 80, 160 ng mL-1 (low, medium and high QC samples, 
respectively) of codeine and were analyzed on three different days 
to determine intra- and inter-day variation. Precision was estimated 
from coefficient of variation (CV%) and accuracy was measured as 
% of recovery. Quantification limit was estimated based on signal 
intensity and noise for the m/z analyte trace (S/N > 10) with precision 
and accuracy less than or equal 20%. 
Codeine stability in plasma was studied under a variety of storage 
and handling conditions using the low, medium and high QC samples. 
Short-term temperature stability was assessed through QC sample 
analysis, kept at ambient temperature for 6 h. Sample stability in 
autosampler was conducted analyzing QC samples kept under the 
autosampler condition (4 °C) for 24 h. Freeze-thaw stability (-20 °C 
in plasma) was checked through three cycles. Long-term stability 
was performed at -20 °C in plasma for 30 days. 
Recovery was calculated by comparing mean analyte peak areas 
extracted from plasma samples versus mean peak areas obtained 
from solutions prepared in mobile phase in the same concentration. 
Matrix effect was evaluated by ion suppression degree due to matrix 
components. Continuous infusion postcolumn of codeine and IS (1 µg 
mL-1) were performed through a syringe pump, while a blank human 
plasma sample was extracted and chromatographed in the conditions 
of on-line SPE. Ion suppression degree was monitored at elution time 
of codeine and IS by continuously acquiring MRM mode.
RESULTS AND DISCUSSION
HPLC-MS/MS condition optimization
Mass spectrometric parameters were optimized to achieve 
maximum scan and product abundance from compounds analyzed. 
Full scan codeine and IS product ion mass spectra are displayed 
in Figure 2. Monolithic columns improve high-throughput due to 
higher separation efficiency at high flow velocities when compared 
to conventional LC columns.16 Svensson et al.9 determined codeine 
retention time of approximately 5 min using solid phase extraction 
(SPE) and conventional C18 column chromatography. Most forensic 
application methods determined codeine with long chromatographic 
run time.6-13 Therefore, mobile phase optimization is important to 
improve peak shape and sensitivity detection as well as codeine and 
tramadol chromatographic run time reduction (IS).
Best chromatographic condition was achieved using a Chromolith 
Performance RP-18e (100 mm x 4.6 mm) column maintained 
at ambient temperature (25° C). Mobile phase was a mixture of 
acetonitrile/acetic acid 10 mmol L-1 pH 3.5 (50:50, v/v) at a flow 
rate of 1 mL min-1. Codeine and IS were eluted at 1.37 and 1.53 min, 
respectively and total analysis run time was 3 min synchronized to 
sample extraction, allowing high-throughput. No interference from 
drug-free human plasma was observed, and method selectivity in 
presence of endogenous plasma compounds was satisfactory. Figure 
3 shows MRM chromatograms of blank plasma, plasma spiked with 
codeine, plasma spiked with IS and QC.
On-line SPE process
On-line SPE technique offers speed, high precision and labor 
decrease for sample clean-up.16 Methods based on liquid-liquid or 
solid-phase off-line extractions for determination of codeine require 
laborious repetitive work and time.15 Furthermore, organic solvents 
employed in this technique expose analyst and environment to 
biohazard.14 In recent publication, Verplaetse and Henion18 determined 
a series of opioids by automated dried blood spot desorption coupled 
on-line SPE-LC-MS/MS method. Although showed excellent 
precision, accuracy and reduced analysis time, this technique was 
not applied a large number of samples or even complete codeine 
pharmacokinetic study. Other few methods were performed based 
upon on-line SPE to determined codeine. However, such methods 
were performed in other matrices and sample extraction steps were 
semi-automated.6,18-22 Liao et al.23 developed a codeine determination 
method with chromatographic run time of 2 min and applied it 
successfully to a bioequivalence study. In spite of results achieved in 
relation to recovery of about 80%, the method based on liquid-liquid 
extraction consists of several steps to clean samples, including 15 min 
mixing, 10 min centrifugation, plus solvent evaporation time at 40 °C. 
Prospeckt 2 system offers a wide range of cartridge sorbents and 
versatility to change a cartridge automatically.16 Hysphere C18 HD 
SPE stationary phase was chosen for sample preparation purpose, 
allowing higher load capacity and more uniform analyte extraction 
reproducibility.24-28 After mobile phase desorbed analytes and 
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Figure 2. Precursor and product ion spectra of codeine (A) and IS (B)
Figure 3. Representative MRM chromatograms of codeine and IS in human plasma: blank plasma sample (A), plasma spiked with codeine 50 ng mL-1 (B), 
plasma spiked with IS 70 ng mL-1 (C) and QC sample LQ (D)
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transferred to analytical column, cartridge was washed with 2 mL 
of mixture acetonitrile/acid formic 20 mmol L-1 pH 3.2 (60/40, v/v) 
and methanol (1 mL). Therefore, no carry-over was observed when 
a blank solution was injected into cartridge after injecting the highest 
calibration point. Cartridge was then physically moved with a robotic 
arm, leaving the extraction clamp set to new sample. Total cycle time 
of 3 min allows 480 samples to be analyzed per day.
Method validation
Matrix effect was evaluated by post-column analyte infusion 
experiments based on method described by Bonfiglio et al.29 
Four different blank plasma sample (including normal, lipemic 
and hemolysed) were extracted under on-line SPE conditions and 
chromatographed. No significant ion suppression effect was observed 
in codeine and IS retention time. 
The recovery of codeine was evaluated with four different 
concentrations 5, 15, 80, 160 ng mL-1 by comparing the peak area 
ratios (peak area of the solution/peak area of the plasma sample 
extracted). Mean extraction recoveries of codeine were 66.62, 62.82, 
60.51 and 75.14%, respectively. Tramadol (IS) average recovery was 
74.57% ranging from 69.89-77.07%. Regarding codeine recovery 
values some studies18-21 also reached similar results, indicating that 
low recovery is a characteristic of these compounds when submitted 
to SPE conditions.
Linearity was evaluated using codeine calibration curves from 5.0 
to 200 ng mL-1. A good linear relationship between peak area ratios 
and concentrations was established. The mean regression equation 
and determination coefficient (r2) from duplicate calibration curves 
on three non-consecutive days were: y = 0.013215(±0.001475)
x + 0.018946(±0.013191) and r2 = 0.998573(±0.001093). Lowest 
concentration calibration standard (5 ng mL-1) was taken as 
quantification limit. 
Precision and accuracy for this method were controlled by 
calculating intra- and inter-day variation at three concentrations 
(15, 80, 160 ng mL-1) of QC samples in six replicates. Intra-day 
mean accuracy ranged from -2.36 to 10%, and intra-day precision 
ranged from 2.33 to 3.65% (CV). Inter-day accuracy ranged from 
0.03 to 3.80%, and inter-day precision ranged from 4.35 to 7.25, 
as shown in Table 2. Although, the toxicological and forensic 
methods6-13 described here are sufficiently precise and accurate for 
the measurement of codeine in human plasma, this current method 
showed excellent results, with intra and inter-day accuracy and 
precision less than 10% and within the ranges specified by ANVISA 
guideline.17 Other automated and pharmacokinetics determination 
of the codeine18-23 also failed to achieve intra-day precision less than 
5% as was obtained in this study. These results demonstrate that this 
method has been effectively optimized, with less sample manipulation 
and higher accuracy and precision as described by Xu et al.16
Codeine stability in human plasma under different storage 
conditions is summarized in Table 3. There was no significant 
degradation at any tested concentration and all CV(%) values between 
post-storage and initial QC samples were within ± 15%. Codeine was 
stable under all conditions described and no stability-related problems 
were encountered during routine sample analysis.
Method application 
This validated on-line SPE-LC-MS/MS method was successfully 
applied to pharmacokinetic study of codeine tablet in 31 healthy 
volunteers following oral administration of 30 mg codeine. High-
throughput sample analyses are very important in studies that require 
a large number of samples. In the present study, 1700 samples were 
analyzed, including clinical samples, calibration curves and QC 
samples. There was no significant change related to backpressure, 
peak asymmetry and retention time reproducibility. Figure 4 shows a 
representative plasma concentration-time profile for codeine.
CONCLUSIONS
An automated LC-MS/MS method has been developed and 
validated for codeine determination in human plasma utilizing 
Table 1. On-line SPE programming
Action Solvent (volume) Velocity Time*
Replaced cartridge - - 10s
Activation Methanol (1 mL) 5 mL min-1 18s
Conditioning Water (1 mL) 5 mL min-1 18s
Sample application 10 mM Acetic acid (0.5 mL) 2 mL min-1 18s
Wash 10 mM Acetic acid (2 mL) 3 mL min-1 52s
Elution Mobile phase 1 mL min-1 20s
Wash acetonitrile/20 mM acid formic (60/40, v/v) (2 mL) 7 mL min-1 24s
Wash Methanol (1mL) 5 mL min-1 18s
Start new cycle - - -
Total time - - 2 min 58s
*Time for each step including syringe fillings.





(ng mL-1) ± SD*
Precision, CV (%) Accuracy, (%)
Intra-day
15 16.50 ± 0.39 2.34 110.00
80 79.92 ± 2.92 3.65 99,90
160 156.23 ± 3.63 2.33 97,64
Inter-day
15 15.57 ± 1.13 7.25 103.80
80 81.72 ± 5.61 6.86 102.15
160 160.04 ± 6.95 4.35 100.03
*Standard deviation.
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on-line solid phase extraction. This method awards compensation 
over those previously reported6-13,23 in terms of time per sample 
clean-up, improved separation speed by monolithic column and 
high-throughput due to fast chromatographic run time synchronized 
to sample extraction (3.0 min). On-line SPE-LC-MS/MS method 
allowed a rapid assay development and sample processing. Method 
was validated the concentration range 5.0-200 ng mL-1. Assay 
performance results indicate that the method is sufficiently precise and 
accurate for routine determination of the codeine in human plasma.
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